Tousled-like kinase-dependent phosphorylation of Rad9 plays a role in cell cycle progression and G2/M checkpoint exit

PLoS One. 2013 Dec 20;8(12):e85859. doi: 10.1371/journal.pone.0085859. eCollection 2013.

Abstract

Genomic integrity is preserved by checkpoints, which act to delay cell cycle progression in the presence of DNA damage or replication stress. The heterotrimeric Rad9-Rad1-Hus1 (9-1-1) complex is a PCNA-like clamp that is loaded onto DNA at structures resulting from damage and is important for initiating and maintaining the checkpoint response. Rad9 possesses a C-terminal tail that is phosphorylated constitutively and in response to cell cycle position and DNA damage. Previous studies have identified tousled-like kinase 1 (TLK1) as a kinase that may modify Rad9. Here we show that Rad9 is phosphorylated in a TLK-dependent manner in vitro and in vivo, and that T355 within the C-terminal tail is the primary targeted residue. Phosphorylation of Rad9 at T355 is quickly reduced upon exposure to ionizing radiation before returning to baseline later in the damage response. We also show that TLK1 and Rad9 interact constitutively, and that this interaction is enhanced in chromatin-bound Rad9 at later stages of the damage response. Furthermore, we demonstrate via siRNA-mediated depletion that TLK1 is required for progression through S-phase in normally cycling cells, and that cells lacking TLK1 display a prolonged G2/M arrest upon exposure to ionizing radiation, a phenotype that is mimicked by over-expression of a Rad9-T355A mutant. Given that TLK1 has previously been shown to be transiently inactivated upon phosphorylation by Chk1 in response to DNA damage, we propose that TLK1 and Chk1 act in concert to modulate the phosphorylation status of Rad9, which in turn serves to regulate the DNA damage response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle Proteins / metabolism*
  • DNA Damage / physiology*
  • Flow Cytometry
  • G2 Phase Cell Cycle Checkpoints / physiology*
  • HeLa Cells
  • Humans
  • Immunoblotting
  • Immunoprecipitation
  • Mutagenesis, Site-Directed
  • Phosphorylation
  • Plasmids / genetics
  • Protein Serine-Threonine Kinases / metabolism*

Substances

  • Cell Cycle Proteins
  • rad9 protein
  • Protein Serine-Threonine Kinases
  • TLK1 protein, human

Grants and funding

This work was supported by the National Cancer Institute of Canada, through funds from the Canadian Cancer Society (grant 016390), and by the Ontario Chapter of the Canadian Breast Cancer Foundation (grant name "BRCA1 Status"). Infrastructure used in the course of this work was purchased with funds from the Canadian Foundation for Innovation Leaders Opportunity Fund (grant 12598) and the Ontario Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.